Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
Medicus Pharma Ltd. (MDCX) filed Offering Circular Supplement No. 11 under Rule 253(g)(2) covering 1,490,000 common shares issuable upon exercise of its Nasdaq-listed public warrants (strike $4.64, expiry 11-15-2029). On 07-22-25 the shares and warrants closed at $3.08 and $1.05, respectively.
The supplement attaches the Form 8-K reporting results of the 22 July 2025 Annual & Special Meeting:
- Auditor ratified: KPMG LLP, 13.26 m for vs 55.7 k withhold.
- Board continuity: all eight nominees re-elected (~10.12 m for; 17 k withhold; 3.19 m broker non-votes).
- Quorum rule raised from 10 % to 33⅓ % (10.13 m for; 5.1 k against) to meet Nasdaq standards.
- Financing flexibility: shareholders authorised issuance of ≥20 % new shares below Nasdaq “minimum price” under the YA II PN Standby Equity Purchase Agreement (10.06 m for; 68.7 k against).
- Chairman protection: Articles amended to require a 75 % board vote to remove the Chair (9.89 m for; 241 k against).
The votes give management new capital-raising capacity and align governance with U.S. listing rules, but also introduce dilution risk and tighten board control. No financial results were disclosed.
Medicus Pharma Ltd. (Nasdaq: MDCX) has entered into a warrant-inducement transaction designed to raise near-term cash and expand its future capital pool.
- Immediate cash: A single accredited holder agreed to exercise 1,340,000 existing $2.80 warrants, delivering approximately $3.75 million gross proceeds (closing expected 14 July 2025). Maxim Group will receive a 6 % cash fee.
- New leverage: In exchange, the holder will receive 2,680,000 five-year “New Warrants” at an exercise price of $3.75. Half the series includes a forced-exercise feature once the 10-day VWAP equals or exceeds $10.00.
- Protective terms: New Warrants contain customary anti-dilution adjustments and Black-Scholes value protection on fundamental transactions.
- Additional financing: Through two SEPA draws (9 & 14 July 2025) the company sold 490,000 shares to Yorkville at an average price of $3.10, raising $1.52 million earmarked partly for debenture pre-payment.
- Use of proceeds: funds will support ongoing clinical trials, working capital and the pending acquisition of Antev Limited.
- Listing/Capital structure: Common shares and $4.64 Public Warrants continue to trade under MDCX and MDCXW. The inducement and SEPA transactions add up to 4.51 million potential new shares, increasing prospective dilution.
Medicus remains an emerging growth company and intends to register New Warrant shares within 120 days.
Transaction overview: On July 14, 2025 Medicus Pharma (Nasdaq: MDCX) entered a Warrant Inducement Agreement with an accredited holder. The holder will immediately exercise 1,340,000 existing warrants at $2.80, generating roughly $3.75 million gross proceeds. In exchange, the investor will receive 2,680,000 new five-year warrants exercisable at $3.75; half include a forced-exercise clause if the 10-day VWAP reaches $10.
The company will pay Maxim Group a 6 % cash fee and intends to allocate net proceeds to ongoing clinical trials, working capital and costs linked to its pending Antev Limited acquisition.
Additional financing: Separately, Medicus sold 490,000 common shares to Yorkville under its Standby Equity Purchase Agreement at an average $3.11 per share, raising $1.52 million earmarked partly for debenture pre-payment.
Capital structure impact: The transactions immediately issue 1.34 million shares and could add up to 2.68 million more upon warrant exercise, plus the 0.49 million SEPA shares—an aggregate potential dilution of ~4.51 million shares, or roughly 10 % of the pre-deal share count (exact base not disclosed). The new warrants are struck 24 % above the last close ($3.03) and may provide further cash if exercised.
Nasdaq prices on 11-Jul-25: common $3.03, public warrants $1.03. The company remains an emerging growth company and will file an S-1 within 120 days to register the resale of the new warrant shares.
Medicus Pharma Ltd. (Nasdaq: MDCX) has entered into a warrant-inducement agreement designed to raise near-term cash while providing investors with additional long-dated equity upside.
Key terms: an accredited institutional holder will immediately exercise 1,340,000 existing $2.80 warrants for gross proceeds of roughly $3.75 million. In exchange, the holder will receive 2,680,000 new unregistered warrants split into two equal series. Both series carry a higher $3.75 exercise price, are exercisable upon issuance and expire five years after closing (expected 14 Jul 2025). One series includes a company call feature that can force exercise if the share price averages ≥ $10 over any 10-day trading window. Standard anti-dilution and fundamental-transaction protections apply.
The company will pay Maxim Group a 6 % cash fee on gross proceeds. Net cash is earmarked for ongoing clinical trials, working capital and costs linked to the pending acquisition of Antev Limited.
Additional capital activity: under its Standby Equity Purchase Agreement (SEPA) with Yorkville, Medicus sold 490,000 common shares on 9 & 14 Jul 2025 at average prices of $3.28 and $3.02, raising $1.52 million. Part of the proceeds will prepay Yorkville debentures. Yorkville may resell these shares under an effective S-1 (File No. 333-287582).
Listing & market data: common shares and $4.64 Nasdaq-listed public warrants trade under symbols MDCX and MDCXW. Last quoted prices on 11 Jul 2025 were $3.03 and $1.03, respectively.
Implications for investors: the transaction strengthens near-term liquidity for clinical and M&A objectives without issuing equity at or below market, but it introduces potential dilution of up to 4.02 million additional shares (already-exercised 1.34 million plus 2.68 million new warrants). Forced-exercise mechanics above $10 could accelerate future cash inflow yet intensify dilution if the share price rises materially. Management remains an emerging growth company and will file an S-1 within 120 days to register the warrant shares.